Navigating Treatment Complexities in First- and Second-Line Therapies for mRCC

In this video, Regina Barragán-Carrillo, MD, of City of Hope, details progress in the treatment of metastatic renal cell carcinoma (RCC), highlighting how survival rates have improved significantly over the past two decades. She discusses the transformative impact of immune checkpoint inhibitors (ICIs), including anti-PD-1 and anti-CTLA-4 agents, and their use in combination with tyrosine kinase inhibitors (TKIs) or as dual ICI regimens. These advances have led to longer survival, enhanced quality of life, and a broader range of therapeutic options. The conversation also addresses the complexities of treatment selection, particularly in first-line therapy and the challenges of managing second-line and refractory disease. Key topics include the importance of balancing efficacy with toxicity, the role of predictive biomarkers, and the need for continued research to refine personalized care strategies. Emerging therapies and clinical trials are discussed as promising avenues to address current unmet needs in RCC treatment.